Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6048397 | 0.68 | NPC1 (0.38) | NPC1ALOX12RAB9ATDP1KDM4E | |
| SCHEMBL427427 | 0.66 | LPO (0.32) | — | |
| SCHEMBL9560023 | 0.64 | KDM4E (0.40) | NPC1ALOX12RAB9ATDP1KDM4E | |
| SCHEMBL28955974 | 0.63 | ATAD2 (0.47) | KDM4E | |
| SCHEMBL2490716 | 0.61 | ADORA2A (0.38) | — | |
| SCHEMBL9770361 | 0.60 | — | — | |
| SCHEMBL11781503 | 0.55 | P2RX4 (0.41) | TDP1KDM4E | |
| SCHEMBL355904 | 0.54 | MPO (0.38) | — | |
| SCHEMBL2384940 | 0.54 | LGMN (0.37) | TDP1KDM4E | |
| SCHEMBL8656134 | 0.53 | ALDH1A1 (0.47) | ALOX12TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 926 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5486603-A | Oligonucleotide having enhanced binding affinity | GILEAD SCIENCES, INC. (US) | 1996-01-23 | — | — | US | claimed |
| US-12638452-B2 | Nanopore assemblies and uses thereof | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260097094-A1 | METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN | INST NAT SANTE RECH MED (FR) | 2026-04-09 | — | — | US | disclosed |
| US-12539510-B2 | Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge | CEPHEID (US) | 2026-02-03 | — | — | US | disclosed |
| US-12517124-B2 | Chimeric receptor for use in whole-cell sensors for detecting analytes of interest | INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-01-06 | — | — | US | disclosed |
| US-20250332186-A1 | Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases | CURELAB ONCOLOGY INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250249278-A1 | METHODS FOR CONTROLLING THE TUMOR CELL KILLING BY LIGHT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-08-07 | — | — | US | disclosed |
| US-20250235492-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING TEAR FILM COMPOSITION TO TREAT CORNEAL DEFECTS | CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER (FR) | 2025-07-24 | — | — | US | disclosed |
| US-12343376-B2 | Methods for inhibiting diazepam binding protein | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-01 | — | — | US | disclosed |
| CN-118949941-A | Nanopore assembly and uses thereof | 牛津纳米孔科技公开有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2001042304-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-RELATED MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001011050-A1 | Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY | AMGEN INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001007074-A1 | VGF SELECTIVE BINDING AGENTS AND METHODS OF TREATING VGF-RELATED DISORDERS | AMGEN, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007477-A1 | VGF POLYPEPTIDES AND METHODS OF TREATING VGF-RELATED DISORDERS | AMGEN, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000074635-A2 | DELIVERY OF SINGLE STRANDED DNA FOR EXPRESSION | MIRUS CORPORATION (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-0848758-A1 | TARGETED NUCLEOTIDE SEQUENCE DELIVERY AND INTEGRATION SYSTEM | Avigen, Inc. (US) | 1998-06-24 | — | — | EP | disclosed |
| WO-1998025630-A1 | TRANSALDOLASE-MEDIATED REGULATION OF APOPTOSIS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997009442-A1 | TARGETED NUCLEOTIDE SEQUENCE DELIVERY AND INTEGRATION SYSTEM | AVIGEN, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1995004064-A9 | POLYNUCLEOTIDE DECOYS THAT IHNIBIT MHC-II EXPRESSION AND USES THEREOF | — | 1995-03-09 | — | — | WO | disclosed |
| WO-1994004548-A1 | CHEMICALLY REVERSIBLE APTAMERS | GILEAD SCIENCES, INC. (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097094-A1 | METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN | DBI, MAP1LC3B, BECN1 | NPC1 400/4885ALOX12 2042/4885RAB9A 1112/4885 |
| US-12539510-B2 | Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge | DNMT3A, DNMT1, NSUN2 | NPC1 4338/4885ALOX12 4589/4885RAB9A 4578/4885 |
| US-20250249278-A1 | METHODS FOR CONTROLLING THE TUMOR CELL KILLING BY LIGHT | TNFRSF9, CD47, CD4 | NPC1 4633/4885ALOX12 3787/4885RAB9A 2356/4885 |
| US-12638452-B2 | Nanopore assemblies and uses thereof | FAM83A, SCNN1G, SCN3A | NPC1 996/4885ALOX12 4497/4885RAB9A 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.